Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HMBD 001

Next Previous
X
Search
Drug Profile

HMBD 001

Alternative Names: 10D1F; anti-HER3 antibody - Hummingbird Bioscience; HMBD-001; HMBD-001-10D1

Latest Information Update: 15 Jun 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hummingbird Bioscience
  • Developer Cancer Research UK; Hummingbird Bioscience
  • Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB-3 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Non-small cell lung cancer
  • Preclinical Colorectal cancer; Prostate cancer; Squamous cell cancer

Most Recent Events

  • 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research
  • 05 Dec 2023 Pharmacokinetic data from a phase I/II trial in Solid tumours presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
  • 23 Oct 2023 Efficacy, adverse events and PK data from phase I/II trial in Solid tumours released by Hummingbird Bioscience

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top